Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies

Retina

Volumn 31, Issue 4, 2011, Pages 654-661

  McCannel, Colin A ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

ARTICLE; BACILLUS CEREUS; BACTERIUM CULTURE; BACTERIUM ISOLATE; CATARACT EXTRACTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENDOPHTHALMITIS; EYE SURGERY; HUMAN; STREPTOCOCCUS; UNITED STATES; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; BACTERIA; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955066891     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820a67e4     Document Type: Article

References (51)

1. Miller JJ, Scott IU, FlynnHWJr, Smiddy WE, Newton J,Miller D. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983-987.
2. Herman DC. Safety of a clean air storage hood for ophthalmic instruments in the operating room. Am J Ophthalmol 1995; 119:350-354.
3. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology 1998;105:1004-1010. (Pubitemid 28268323)
4. Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). OphthalmicSurg Lasers 2002;33:373-378. (Pubitemid 44714242)
5. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567. (Pubitemid 351589565)
6. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
8. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542. (Pubitemid 44748725)
9. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.e1-633.e4.
10. Kopel AC, Carvounis PE, Holz ER. Bacillus cereus endophthalmitis following intravitreous bevacizumab injection. Ophthalmic Surg Lasers Imaging 2008;39:153-154. (Pubitemid 351619795)
11. Pilli S,KotsolisA, SpaideRF, et al.Endophthalmitis associated with intravitreal anti-vascular endothelial growthfactor therapyinjections in an office setting. Am J Ophthalmol 2008;145:879-882.
12. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
13. Brown DM,MichelsM, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57.e5-65.e5.
14. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-605.
15. Bhavsar AR, Googe JM Jr, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583.
16. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29:1213-1217.
17. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116:1225.e1.
18. Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol 2009;148:66.e1-69.e1.
19. Chen E, Ho AC, Garg SJ, Brown GC, Kaiser RS. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging 2009;40:192-194.
20. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010;117:298-302.
21. Aggio FB, Farah ME, de Melo GB, d'Azevedo PA, Pignatari AC, Hofling-Lima AL. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2007;21:408-409. (Pubitemid 46358806)
22. Alkuraya HS, Al-Kharashi AS, Alharthi E, Chaudhry IA. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 2009;29:411-413.
23. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009; 23:2187-2193.
24. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363. (Pubitemid 351733229)
25. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
26. Lee SH, Woo SJ, Park KH, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond) 2010;24:226-232.
27. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
28. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992.e6-1001.e6.
29. The Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996;122:830-846.
30. Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008;115:473-476.
31. Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25- gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina 2008;28:138-142.
32. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116:1498-1501.
33. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113:1479-1496.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
35. Gordon DF, Jong BB. Indigenous flora from human saliva. Appl Microbiol 1968;16:428-429.
36. McCarthy C, Snyder ML, Parker RB. The indigenous oral flora of man. I. The newborn to the 1-year-old infant. Arch Oral Biol 1965;10:61-70.
37. Veringa E, van Belkum A, Schellekens H. Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. J Hosp Infect 1995;29:316-318.
38. Sheretz RJ, Reagan DR, Hampton KD, et al. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med 1996;124:539-547.
39. O'Kelly SW, Marsh D. Face masks and spinal anaesthesia. Br J Anaesth 1993;70:239.
40. McLure HA, Talboys CA, Yentis SM, Azadian BS. Surgical face masks and downward dispersal of bacteria. Anaesthesia 1998;53:624-626. (Pubitemid 28342392)
41. Trautmann M, Lepper PM, Schmitz FJ. Three cases of bacterial meningitis after spinal and epidural anesthesia. Eur J Clin Microbiol Infect Dis 2002;21:43-45. (Pubitemid 34158505)
42. Auroy Y, Benhamou D, Bargues L, et al. Major complications of regional anesthesia in France: the SOS Regional Anesthesia Hotline Service. Anesthesiology 2002;97:1274-1280. (Pubitemid 35265584)
43. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004:101:950-959. (Pubitemid 39288046)
44. Videira RL, Ruiz-Neto PP, Brandao Neto M. Post spinal meningitis and asepsis. Acta Anaesthesiol Scand 2002;46: 639-646. (Pubitemid 34632660)
45. Philips BJ, Fergusson S, Armstrong P, Anderson FM, Wildsmith JA. Surgical face masks are effective in reducing bacterial contamination caused by dispersal from the upper airway. Br J Anaesth 1992;69:407-408.
46. Reeves KD, Horvat RT. Aerosolized alpha-hemolytic Streptococcus as a cause of knee sepsis after intra-articular injection: predisposing factors. Am J Phys Med Rehabil 2010;89:77-82.
47. Shewmaker PL, Gertz RE Jr, Kim CY, et al. Streptococcus salivarius meningitis case strain traced to oral flora of anesthesiologist. J Clin Microbiol 2010;48:2589-2591.
48. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991;98: 639-649; discussion 650.
49. Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother 2009;10: 2119-2126.
50. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19. (Pubitemid 39391785)
51. Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Available at: www.cdc.gov/ncidod/dhqp/pdf/guidelines/isolation2007.pdf. Accessed March 29, 2010.